Sphera Funds Management LTD. lifted its stake in shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) by 10.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 295,199 shares of the company’s stock after acquiring an additional 27,850 shares during the quarter. Sphera Funds Management LTD. owned about 1.42% of Allena Pharmaceuticals worth $3,170,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in Allena Pharmaceuticals in the 2nd quarter valued at about $242,000. Alps Advisors Inc. purchased a new stake in Allena Pharmaceuticals in the 2nd quarter valued at about $391,000. Rhumbline Advisers purchased a new stake in Allena Pharmaceuticals in the 2nd quarter valued at about $133,000. Bank of New York Mellon Corp grew its holdings in Allena Pharmaceuticals by 205.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,137 shares of the company’s stock valued at $406,000 after buying an additional 20,954 shares during the period. Finally, Schwab Charles Investment Management Inc. purchased a new stake in Allena Pharmaceuticals in the 2nd quarter valued at about $282,000. Institutional investors own 84.39% of the company’s stock.
Several research firms have commented on ALNA. Zacks Investment Research cut Allena Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Jefferies Financial Group began coverage on Allena Pharmaceuticals in a report on Thursday, November 8th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Wedbush restated a “buy” rating and issued a $38.00 price target on shares of Allena Pharmaceuticals in a report on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $29.14.
NASDAQ ALNA opened at $9.26 on Friday. The stock has a market capitalization of $189.76 million and a PE ratio of -1.93. Allena Pharmaceuticals Inc has a 1-year low of $6.13 and a 1-year high of $17.56. The company has a current ratio of 14.75, a quick ratio of 14.75 and a debt-to-equity ratio of 0.17.
Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings data on Wednesday, November 7th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.01. Sell-side analysts expect that Allena Pharmaceuticals Inc will post -1.79 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Allena Pharmaceuticals Inc (ALNA) Stake Increased by Sphera Funds Management LTD.” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/12/08/allena-pharmaceuticals-inc-alna-stake-increased-by-sphera-funds-management-ltd.html.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Story: What is the float in trading stocks?
Want to see what other hedge funds are holding ALNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allena Pharmaceuticals Inc (NASDAQ:ALNA).
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.